Connect with us

Cannabis News

GOP Senator Says Congress Must ‘Step Up’ And Regulate Marijuana, While Exploring Its ‘Efficacy’ For PTSD And Pain

Published

1 month ago

on

A Senator GOP says that the federal government needs “step” and must explore the regulatory framework of Marijuana and, that it should be a way to study the “efficiency of” efficiency “for health conditions.

Thom Tillis (R-NC) made comments made by the Senate Judiciary Commission on Wednesday, where President Donald Trump and the judicial denominator Candidate drugs testified for the Director of Office of National Control Policy (Ondcp) Before possible votes of assertion.

Tillis said that the Cory Booker (D-NJ) had made points about Cannabis policy “when they are very well taken”, “Congress is not playing his work.”

As more states are legalized, public support will be worried about public support “if not serious about regulatory regulations,” argued the Republican Senator.

Listen to the senator’s remarks about marijuana regulation 2:44:10:

“Congress must take step and try to manage (and) in the areas that exploit its effectiveness, the treatment and pain of people with PTSD, Tillis said.” But we have to step. “

“In the time left here, we hope we can get something,” he said he did not reset again.

The earlier hearing, Sara Carter, Sara Carter (name Sara Bailey). It is what he has been addressed to the questions, and the administration kept holding “all options” on the table. While describing the reform of cannabis as “bipartisan”.

The book indicated that Carter had support about access to Marijuana Marijuana in 2023Congress has had “Bipartisan’s auditions here about military workers talking about the transformative impact of post-traumatic stress disorder (PTSD)”.

As the senator agrees to end the banned banabis ban, Joe Biden began under the former president of Joe Biden and Trump said that he would definitely take the decision in the last month “would be a step in the right direction.”

The Tillis did not specifically weighed in the proposal to move cannabis to program II (CSA) of Substance Act III (CSA). But the echo had the need to evaluate the regular marijuana framework of Marijuana in the federal level of Marijuana.

–
Marijuana is a moment Monitoring of hundreds of cannabis, psychedelic and drug policy invoices This year’s state legislatures and congresses. Patreon supporters At least $ 25 / monthly enter our interactive maps, graphs and listening to the listening calendar, so they do not lose development.

Learn more about us Marihuana Bill Tracker and become Assistant Patreon to get access.
–

In the Judiciary Committee on June, Tillis said Marijuana legalization opponents “They lost” the struggle to keep ban And the “time” is to cope with this reality, creating a regulatory framework for treatment of cannabis “in the same way we do alcohol and tobacco, to establish policies without federal intervention.

In February, the senator also raised the subject during the Senate Bank Committee, Saying “Rexamine (Marijuana Federal Laws) saying”. “ At the same time, “We are sure it shouldn’t be done” legislation that would accept legislation to prevent penalizing the banks working with the State Canavy business.

“If someone wants to practice the rules of the road and want to make the industry, in a cohesive and sustainable way, the skirt is not permanently, it is still illegal at the federal level.

Tillis said that last December, hopeful conference will be “discussion” Marijuana may create a federal regulatory framework In 2025, he added that he would personally vote to legalize cannabis federally.

Last year, Senator also said “Supports the creation of a comprehensive regulations Marijuana treats like tobacco, “argued” The federal government must represent a safe way to allow this market to happen. “

Tillis in April Sen. TED Budd (R-NC) entered Federal, State and Local Officials What to Ask The steps were enforcing the marijuana ban As Indian tribes was prepared for recreational cannabis sales within its land within North Carolina.

Meanwhile, in 2017, Tillis also collaborated with bandides in a bill Pay attention to researchers to marijuana access for its medical benefits And the National Institute of Abuse Drugs (NIDA) requires the development of good manufacturing practices for growing and producing research canvas.

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

Become patreon guard!

(Tagstotranslate) highlighted

Related Topics:
Continue Reading

Cannabis News

Opening the doors to standardized cannabis propagation

Published

13 hours ago

on

October 26, 2025

By

Twenty cannabis growers from all over Europe and the world recently gathered in Austria for another industry event: a one-day invitation-only masterclass on cannabis propagation, hosted by Fluence, one of Europe’s largest cannabis clone producers, at the Flowery Field in Vienna.

The day included lectures, live demonstrations and a rare guided tour through a facility that is usually closed to outsiders. “It was a good mix of practice and theory,” says Fluence’s Theo Tekstra. “In the morning we had a theoretical block, then we had an in-depth tour of the tissue culture laboratory and the mother plant and reproduction areas, and in the afternoon a practical workshop. Everyone saw and participated in the whole process.”

© Fluence BioengineeringA cannabis tissue culture clone in the early rooting hardening phase was demonstrated at the Flowery Field hands-on session, demonstrating propagation techniques with Fluence LED lighting.

Historical installation
Flowery Field was founded by Alexander Klima, a former law student who noticed that Austrian regulations discriminated between plants and their uses. In practice, this means that cannabis can be sold as an ornamental plant, as long as it is not harvested for consumption.

What started as a small shop selling houseplants along with cannabis cuttings, has since become a major production site, with a hundreds of square meters of mother plant and tissue culture laboratory where eight technicians work every day. The company now focuses entirely on cannabis clones, supplying customers in Austria and neighboring countries, often with same-day delivery to selected locations.

Standardized expansion
For Franz Joseph Sima, Fluence’s long-time propagation specialist, the masterclass aimed to show how standard procedures transform the mother and clone phases of cannabis production. “Many producers still have challenges in the expansion phase,” he said. “At Flory Field, these processes have been refined over twenty years. We wanted participants to see how a consistent and commercially viable system works in practice.”

The workshop covered everything from mother plant maintenance and replacement schedules, to light intensity, watering and pest management. The attendees received the full procedure afterwards. “The only condition,” says Franz, “was to be there.”

© Fluence BioengineeringFranz Josef Sima, Cannabis Research & Plant Specialist at Fluence, guiding participants through best practices in mother plant maintenance and clone cutting.

From tissue culture to mother plant
Participants followed the entire production chain, from tissue culture and virus testing in the laboratory, to cutting and preparation of clones. Flowery uses PCR testing to ensure cultivar stability and purity, a practice more common in pharmaceutical or ornamental horticulture than cannabis.

“The contrast was striking,” says Theo. “You have this sterile white lab on one side, and on the other a fully commercial clone factory based on the mother plants. Seeing both under one roof gave people a real sense of scale.”

Opening the doors
One of the main takeaways from the day was the atmosphere of openness. “In the Dutch horticulture industry, growers thrived by visiting each other and sharing knowledge,” says Theo. “In cannabis, everyone tends to close their doors. Events like this are a step to change that.”

The small group format helped. What began as quiet observation soon turned into a back-and-forth of ideas, with growers comparing notes, solving problems, and sharing their methods.

© Fluence BioengineeringAttendees of the Fluence Propagation Masterclass at Flowery Field in Vienna, a meeting of cannabis cultivation professionals from all over Europe.

Interest in the event exceeded expectations, Franz and Theo both say, and Fluence is already considering repeating the format. “We can do another show in the same place, and maybe even one in the US. It’s something that people can clearly see. In cannabis, very few cloning procedures have been proven for a decade or more, so showing something that has stood the test of time makes a big difference.”

For one day, Flowery Field opened its doors, its laboratories and its mother rooms to a small but focused group of professionals. “In a sector where practical knowledge tends to be kept close to the box, that alone was worth a visit,” concludes Theo.

If you are interested in participating in Fluence Masterclass events across Europe, please get in touch (email protected)

For more information:
fluency
https://fluence-led.com/

Continue Reading

Cannabis News

Oregon Officials Seek To Dismiss Psilocybin Access Lawsuit From Homebound Patients

Published

13 hours ago

on

October 26, 2025

By

“Delays in enabling access mean that patients who achieved relief from debilitating anxiety and depression will die in unrelieved suffering.”

Author: Jack Gorsline, Filter

A The legal battle between the state of Oregon and a group of psilocybin boosters has intensified after the state asked for a second time to throw out their lawsuit.

The group originally sued the Oregon Health Authority in 2024 to prevent disabled and dying Oregonians from accessing psilocybin under the state’s Psilocybin Services Act. At the heart of their complaint is that by limiting services to licensed centers and excluding those who cannot travel, the state is violating the Americans with Disabilities Act (ADA).

The plaintiffs, a group of specialty psilocybin suppliers, filed their brief in a federal District Court in Oregon on October 10, challenging the state’s second attempt to dismiss the case.

The Oregon Health Authority (OHA) filed a motion for judgment on the allegations that the plaintiffs lacked standing to state a claim under the ADA. terminally ill and disabled customers.

That motion was followed by a similar motion filed by OHA and a motion to dismiss the case on similar grounds. it was denied in June

Attorneys for the plaintiffs argue that the OHA is trying to avoid reviewing the merits of the case, thereby perpetuating the illegal exclusion of a vulnerable population.

“Plaintiffs’ promoters have complained enough on their behalf and on behalf of their disabled and dying clients,” said Kathryn Tucker of the National Psychedelic Association, one of the attorneys representing them.

He said the state’s position attempts to sidestep the ADA compliance requirement in the operation of the Psilocybin Services Act.

“OHA seeks to avoid compliance with the ADA in the operation of the PSA, as it unlawfully discriminates against Oregonians,” Tucker said. The filter. “Delays in enabling access mean that patients who achieved relief from debilitating anxiety and depression will die in unrelieved suffering.”

The Psilocybin Services Act, passed by Oregon voters in 2020 to establish a legal and regulatory framework to oversee the use of psilocybin, includes legislative findings and detailed statements of goals that indicate the intent to serve populations such as the terminally ill. The plaintiffs in the lawsuit say that the existing rules, which mandate only service at authorized centers, directly contradict that goal.

The plaintiffs are seeking a court order to require OHA to develop a process for domestic service as a reasonable accommodation, and to notify all licensed facilitators that such accommodations are permitted without fear of disciplinary action.

The ongoing litigation highlights the tension between the state’s innovative regulatory framework and the federal Americans with Disabilities Act, which requires public entities to provide reasonable accommodations to ensure services are accessible to people with disabilities. A previous ruling denying OHA’s motion to dismiss suggested that requiring compliance with the ADA—such as access accommodations—would not necessarily compel the state to violate federal law against the distribution of a Schedule I controlled substance.

However, OHA says that current state law, as written, does not provide a legal means to consume psilocybin outside of a licensed service center, and that accommodating home use would violate the statute. This attitude leaves facilitators who want to serve domestic clients in a precarious situation, at risk of losing their licenses or worse if they provide services outside of regulated centers.

Oregon Health Authority officials did not immediately respond The filterrequests for comments.

Meanwhile, the Psilocybin Services Act was intended to help prevent access to a key population in Oregon. The plaintiffs say the delay in providing accessible services has had far-reaching consequences, especially for terminally ill patients who have limited time to potentially transform the rest of their lives.

If the federal court once again denies OHA’s motion to dismiss the case, it will move closer to deciding whether the state must make accommodations for those clients to perform psilocybin services at home. The result could significantly expand access to the state’s pioneering psilocybin program. It may also affect how other states design their programs.

“We hope the Court will decline to avoid merits review, move the case forward, and ensure access to disabled and dying Oregonians, who are among those most likely to benefit from psilocybin services,” Tucker concluded.

This the article Originally published by the author The filteran online magazine that deals with drug use, drug policy and human rights from a harm reduction perspective. Keep the filter on Bluesky, X or Facebookand sign up for their newsletter.

user photo Wikimedia/Staff.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Local startup expands to 32,000-square-foot cannabis processing facility

Published

2 days ago

on

October 25, 2025

By











Founded in 2018 by six Greek graduates as a CBD company, NOWAVE’s products can be found in 90 percent of New York state’s legal cannabis dispensaries.

“We started with a 300-square-foot space behind a retail store — actually a vape shop,” recalls founder Brian Lane. “((We) started perfecting our gummies, sending them out to vape shops all over the country. The next thing you know, we found ourselves making quite a few gummies. We were self-taught in all of our product types, and now we’ve grown from that 300 square foot space to where we are right now.”

Approximately 100 people work at the Chili facility, producing hemp and CBD products and processing cannabis into edibles, vaping products, and even carbonated beverages containing THC, the psychoactive ingredient in marijuana.

NOWAVE manufactures products for brands including Off Hours, Eaton Botanicals and Weed Water. The company also makes some of the only vegan gummies on the market.

Read more at 13 Yes










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media